| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
91,010,000 |
| Market
Cap: |
102.84(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.3801 - $19.19 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 6.8 |
| Insider 6 Months : 6.8 |
| Insider 3/6 Months : 13.9 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile FibroGen is a biopharmaceutical company that developes and commercializes a pipeline of therapeutics. Co. applies its capability in hypoxia-inducible factor (HIF) biology and connective tissue growth factor (CTGF) biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, Co.'s main product, is an inhibitor of HIF-prolyl hydroxylase activity that acts by stimulating the body's natural pathway of erythropoiesis or red blood cell production. Pamrevlumab is Co.'s human monoclonal antibody that inhibits the activity of CTGF for the treatment of idiopathic pulmonary fibrosis, locally advanced unresectable pancreatic cancer, and Duchenne muscular dystroph.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
50,000 |
50,000 |
50,000 |
50,000 |
| Total Buy Value |
$95,470 |
$95,470 |
$95,470 |
$95,470 |
| Total People Bought |
1 |
1 |
1 |
1 |
| Total Buy Transactions |
1 |
1 |
1 |
1 |
| Total Shares Sold |
0 |
0 |
89,840 |
259,386 |
| Total Sell Value |
$0 |
$0 |
$1,433,580 |
$4,794,856 |
| Total People Sold |
0 |
0 |
12 |
12 |
| Total Sell Transactions |
0 |
0 |
21 |
48 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Kurkijarvi Kalevi |
Director |
– • – |
2021-02-17 |
4 |
OE |
$28.65 |
$171,900 |
D/D |
6,000 |
39,100 |
|
- |
|
| Kurkijarvi Kalevi |
Director |
– • – |
2021-01-19 |
4 |
AS |
$43.38 |
$260,280 |
D/D |
(6,000) |
33,100 |
|
-52% |
|
| Kurkijarvi Kalevi |
Director |
– • – |
2021-01-19 |
4 |
OE |
$19.05 |
$114,300 |
D/D |
6,000 |
39,100 |
|
- |
|
| Kurkijarvi Kalevi |
Director |
– • – |
2021-01-14 |
4 |
AS |
$40.04 |
$240,200 |
D/D |
(5,999) |
33,100 |
|
-52% |
|
| Kurkijarvi Kalevi |
Director |
– • – |
2021-01-14 |
4 |
OE |
$19.05 |
$114,281 |
D/D |
5,999 |
39,099 |
|
- |
|
| Conterno Enrique A |
Chief Executive Officer |
• • – |
2021-01-06 |
4 |
D |
$38.31 |
$207,295 |
D/D |
(5,411) |
55,273 |
|
- |
|
| Schoeneck James A |
Director |
– • – |
2021-01-04 |
4 |
OE |
$9.78 |
$58,650 |
D/D |
6,000 |
15,400 |
|
- |
|
| Kurkijarvi Kalevi |
Director |
– • – |
2020-12-28 |
4 |
AS |
$40.39 |
$242,455 |
D/D |
(6,001) |
33,100 |
|
-48% |
|
| Kurkijarvi Kalevi |
Director |
– • – |
2020-12-28 |
4 |
OE |
$18.34 |
$110,059 |
D/D |
6,001 |
39,101 |
|
- |
|
| Yu K Peony |
Chief Medical Officer |
• – – |
2020-12-16 |
4 |
AS |
$41.61 |
$139,394 |
D/D |
(3,350) |
192,292 |
|
-47% |
|
| Controneo Pat |
SVP, Finance and CFO |
• – – |
2020-12-15 |
4 |
AS |
$43.60 |
$133,765 |
D/D |
(3,068) |
266,144 |
|
-48% |
|
| Kouchakji Elias |
SVP, Clinical Dev, Drug Safety |
• – – |
2020-12-07 |
4 |
D |
$41.99 |
$114,549 |
D/D |
(2,728) |
131,767 |
|
- |
|
| Yu K Peony |
Chief Medical Officer |
• – – |
2020-12-07 |
4 |
D |
$41.99 |
$138,231 |
D/D |
(3,292) |
195,642 |
|
- |
|
| Controneo Pat |
SVP, Finance and CFO |
• – – |
2020-12-07 |
4 |
D |
$41.99 |
$126,558 |
D/D |
(3,014) |
269,212 |
|
- |
|
| Chung Christine |
SVP, China Operations |
• – – |
2020-12-07 |
4 |
D |
$41.99 |
$127,608 |
D/D |
(3,039) |
150,576 |
|
- |
|
| Eisner Mark |
Incoming Chief Medical Officer |
• – – |
2020-12-01 |
4 |
A |
$0.00 |
$0 |
D/D |
35,000 |
35,000 |
|
- |
|
| Kouchakji Elias |
SVP, Clinical Dev, Drug Safety |
• – – |
2020-11-17 |
4 |
OE |
$14.58 |
$103,220 |
D/D |
7,082 |
134,495 |
|
- |
|
| Yu K Peony |
Chief Medical Officer |
• – – |
2020-09-16 |
4 |
AS |
$44.01 |
$147,478 |
D/D |
(3,351) |
198,934 |
|
9% |
|
| Controneo Pat |
SVP, Finance and CFO |
• – – |
2020-09-15 |
4 |
AS |
$43.63 |
$133,944 |
D/D |
(3,070) |
272,226 |
|
12% |
|
| Kouchakji Elias |
SVP, Clinical Dev, Drug Safety |
• – – |
2020-09-08 |
4 |
D |
$42.16 |
$115,012 |
D/D |
(2,728) |
127,413 |
|
- |
|
| Yu K Peony |
Chief Medical Officer |
• – – |
2020-09-08 |
4 |
D |
$42.16 |
$138,749 |
D/D |
(3,291) |
202,285 |
|
- |
|
| Controneo Pat |
SVP, Finance and CFO |
• – – |
2020-09-08 |
4 |
D |
$42.16 |
$127,070 |
D/D |
(3,014) |
275,296 |
|
- |
|
| Chung Christine |
SVP, China Operations |
• – – |
2020-09-08 |
4 |
D |
$42.16 |
$128,082 |
D/D |
(3,038) |
153,615 |
|
- |
|
| Yu K Peony |
Chief Medical Officer |
• – – |
2020-09-03 |
4 |
AS |
$50.89 |
$508,900 |
D/D |
(10,000) |
205,576 |
|
3% |
|
| Yu K Peony |
Chief Medical Officer |
• – – |
2020-09-03 |
4 |
OE |
$18.00 |
$180,000 |
D/D |
10,000 |
215,576 |
|
- |
|
1240 Records found
|
|
Page 8 of 50 |
|
|
0.04 (3.42%) 
